Withaferin A (WA), isolated from Indian medicinal plant Withania somnifera has weak antitumor and radiosensitizing property. The present investigation was planned to evaluate the tumor sensitizing effect of WA with or without local hyperthermia on the response of B16F1 melanoma to fractionated and acute radiotherapy. C57BL mice bearing tumors of 100 ± 10mm3 were treated with fractionated radiotherapy (RT, 2Gy x 5 days/week, 4 weeks), withaferin A (15mg/kg, i.p., 5 days/ week, 3 weeks), local hyperthermia (HT, 43°C once a week, 3 weeks) and their combinations, or acute RT (40Gy), WA (40mg/kg), HT (43°C, 30min) and their combinations. Treatment response was studied by tumor regression, growth delay and animal survival. Acute RT+HT produced 50% partial response which increased to 62.5% with combination of WA. In fractionated regimen, trimodality combination resulted in 100% PR. Acute RT+HT and WA+RT produced similar increase in growth delay (GD) compared to RT alone which further increased in trimodality treatment. Fractionated WA+RT+HT for 3 weeks produced a higher GD and survival than all other treatments. In conclusion, WA is a better radiosensitizer than HT in fractionated regimen and the response of radioresistant tumors like melanoma can be significantly enhanced by combining nontoxic doses of WA with fractionated RT, with or without HT, allowing decrease in radiation dose.
Introduction
The B16F1 mouse melanoma is a relatively radioresistant tumor. It is difficult to completely destroy a tumor of 100 mm 3 by radiotherapy alone, as it contains a large fraction of hypoxic cells. High radiation doses needed to eliminate such tumors will cause severe normal tissue reactions, which will not be tolerated by the patients. Experimental evidence indicates that combining chemotherapy with radiation and hyperthermia can increase the therapeutic outcome and reduce the normal tissue toxicity. [1] [2] [3] Highdose fractions of 10 Gy for 5 consecutive days have been found to increase tumor response, resulting in 25% complete cure. 4 However, such doses/fraction are not practicable in the clinic, as the patient may not be able to tolerate them. If similar radiosensitization can be achieved with conventional 2-Gy fraction radiotherapy, it can be used for the benefit of cancer patients in the treatment of radioresistant tumors.
Our earlier study has shown that trimodality treatment involving radiation and withaferin A can significantly enhance the radiation response of transplanted mouse tumors 5 and addition of hyperthermia can further increase the effect. 4 However, these studies have used single or a few high doses of radiation (10-50 Gy), which is not applicable in clinical radiotherapy. Therefore, the present study was undertaken to see if use of withaferin A in combination with the conventional fractionated radiotherapy could improve the treatment outcome and prolong survival in mice.
Materials and Methods Tumor
B16F1 melanoma was grown in adult C57BL mice. The details of animals and tumor propagation are described elsewhere. 6 Drug Withaferin A (WA), a naturally occurring steroidal lactone, was isolated from the alcoholic extract of dried root powder of the Indian medicinal plant Withania somnifera, as described earlier. 7 WA was dissolved in a few drops of absolute ethanol and a homogeneous suspension was made with 0.5% carboxymethyl cellulose (CMC) shortly before use.
Irradiation
Animals were anesthetized by intraperitoneal (i.p.) injection of 50 mg/kg ketamine and 0.25 mg/mouse of diazepam. Tumors were exposed locally to gamma radiation from a 60 Co teletherapy (Theratron 780C, Theratronics, Ottawa, Canada) unit in a field of 5 × 5 cm, at a dose rate of 1.6 Gy/min.
Hyperthermia
Animals were anesthetized and hyperthermia was applied locally by immersing the tumors in a preheated thermostat controlled water bath (PC 20B, Julabo, Seelbach, Germany), as described earlier. 6 
Treatments
The animals bearing tumors of 100 mm 3 were divided into groups of 8 to 10 and treated as follows.
Acute dose regimen
Group 1. Control: Sham treated Group 2. Radiation (RT) alone: Tumors were exposed locally to 40 Gy gamma radiation. Group 3. Hyperthermia (HT) alone: Tumors were exposed locally to 43°C for 30 minutes. Group 4. Withaferin A (WA) alone: Animals were injected intraperitoneally (i.p.) with 40 mg/kg body weight of WA. Group 5. RT + HT: Tumors were exposed locally to 30 Gy gamma radiation, immediately followed by HT. Group 6. WA + RT: Animals were injected i.p. with 40 mg/kg WA and 1 hour later the tumors were exposed locally to 30 Gy gamma radiation. Group 7. WA + HT: Animals were injected i.p. with 40 mg/kg WA and 1 hour later the tumors were exposed to HT. Group 8. WA + RT + HT: Animals were injected i.p.
with WA and 1 hour later the tumors were exposed locally to 30 Gy gamma radiation followed immediately by HT.
Fractionated dose regimen
Group 1. RT alone: Tumors were exposed locally to 2 Gy gamma radiation daily for 5 days a week, for 4 weeks (total dose = 40 Gy). Group 2. HT alone: Tumors were exposed locally to 43°C, 30 minutes, once a week for 3 weeks. Group 3. WA alone: Animals were injected i.p. with 15 mg/kg WA daily, 5 days a week, for 3 weeks. Group 4. RT + HT: Tumors were exposed locally to 2 Gy daily, 5 days a week, for 3 weeks (total dose 30 Gy), and HT immediately after 1st, 6th, and 11th RT fractions. Group 5. WA + RT: Animals were injected i.p. with 15 mg/kg WA daily, 5 days a week, for 3 weeks (total dose = 225 mg/kg) 1 hour before each RT fraction. Group 6. WA + HT: Animals were injected i.p. with 15 mg/kg WA daily, 5 days a week, for 3 weeks and local HT to the tumor 1 hour after the 1st, 6th, and 11th WA dose. Group 7. WA + RT + HT: Animals were injected i.p. with 15 mg/kg WA daily, 5 days a week, for 3 weeks, 1 hour before each RT fraction, and HT immediately after the 1st, 6th, and 11th RT fraction.
The animals were observed for 120 days. Tumor diameter was measured in 3 perpendicular planes (D1, D2, and D3) using Vernier calipers and tumor volume (V) was calculated by the formula V = p/6 × D1 × D2 × D3.
Parameters
Complete response (CR%). The percentage of animals showing complete disappearance of tumor at the primary site, without any regrowth within 120 days of observation.
Partial response (PR%). Percentage of animals showing more than 50% regression in tumor size from the treatment volume.
Growth delay (GD). Difference in time, in days, between the treated and control tumors to attain 5 times the treatment volume.
All the studies were conducted according to the guidelines of the Committee for the Purpose of Control and Supervision of Experimentation on Animals (CPCSEA), Government of India and approved by the Institutional Animal Ethics Committee.
Statistical Analysis
The data were analyzed by one-way analysis of variance (ANOVA). The interaction between the different treatments, when used in combination, was determined from the index of synergy. 8
Results

Tumor Regression
Single dose regimen. None of the treatments, either as acute dose or in fractionated regimen, produced any complete response (CR). Acute dose treatment with RT (40 Gy) or WA (40 mg/kg) individually did not result in any partial response (PR) either. HT (43°C, 30 minutes) resulted in 10% PR, which was similar to that obtained when WA was given 1 hour before acute RT. HT immediately after RT increased the PR to 50%, whereas WA + HT combination did not have any advantage over HT alone. However, the combination of all the 3 modalities resulted in a significantly higher PR (66%) than that obtained after all the single as well as bimodality treatments (Table 1) .
Fractionated dose regimen. Neither the single modality regimens nor the bimodality treatments WA + RT and WA + HT could produce any partial response, whereas the combination of RT with HT resulted in 22% PR. However, when 15 mg/kg WA was given 1 hour before each 2 Gy, with HT after 1st, 6th, and 11th fractions of WA + RT, the PR increased to 100% (Table 1) .
Tumor Growth Pattern
Tumor growth curves were plotted with volume on the Y axis against posttreatment days on the X axis.
Single dose regimen. Control tumors showed exponential growth, whereas RT, WA, and HT individually produced a small initial delay, followed by exponential growth; RT was more effective than either WA or HT. The combination of WA with HT did not have any major advantage over RT alone, whereas WA + RT and RT + HT resulted in higher, but almost similar shift in the growth curve to the right. The trimodality combination, where WA was injected 1 hour before RT, immediately followed by local HT, gave the maximum tumor response ( Figure 1) .
Fractionated dose regimen. WA and RT, individually gave a similar tumor growth curves and resulted in exponential tumor growth, even though the curve was shifted to the right. Tumors exposed to fractionated RT showed an initial increase in volume to about 4 times the treatment volume during the first 2 weeks of treatment, after which there was a decrease in volume to a minimum after 20 fractions, followed by regrowth at the same rate as in control. Fractionated RT resulted in an initial increase in tumor volume during the first week of treatment; then the tumor showed a regression, followed by regrowth from about 20 days of treatment. Bimodality treatments WA + HT and RT +HT for 3 weeks were not as effective as RT alone. But the combination of WA at 15 mg/kg body weight before every fraction of RT for 3 weeks produced a higher regression and shifted the growth curve to the right considerably compared with RT alone for 4 weeks. WA in combination with RT also reduced the initial increase in tumor volume compared to RT alone treatment. The combination of all 3 modalities in a 3-week treatment regimen resulted in regression of tumor to one fifth the treatment volume, and slowing of tumor regrowth, compared with all other treatments, including the single dose trimodality regimen (Figure 2 ).
Tumor Growth Delay
Single dose regimen. RT produced a growth delay of >20 days, which was highly significant compared to that produced by WA and HT, both of which could induce a delay of less than 6 days ( Figure 3 ). The bimodality treatments WA + RT and RT + HT produced almost similar effects and synergistically increased the growth delay, which was significantly higher than RT alone, whereas WA + HT had a subadditive effect and was less effective than RT alone. The combination of all three modalities, that is, WA once before RT, immediately followed by HT, increased the growth delay to ~41 days, almost double that seen after RT alone treatment and highly significant compared with all single and bimodality treatments.
Fractionated treatment regimen. RT alone for 4 weeks produced GD of ~33 days, which was significantly higher than that produced by 40 Gy given as a single dose (Figure 3 ). HT once a week for 3 weeks and WA daily for 3 weeks and their combination were less efficient than RT alone in increasing GD. The combination of RT + HT produced a subadditive increase in GD; the delay was significantly higher than after the individual modality treatments as well after the combination in acute dose. When WA was combined with RT, there was a synergistic increase in the GD, which was significantly higher than after RT fractionation for 4 weeks as well as the WA + RT combination in acute doses.
Animal Survival
None of the treatments, whether as acute doses or in fractionated regimen, gave any tumor free survival. In sham-treated control group, the mean survival time (MST) was ~41 days. The first mortality was recorded 32 days after the tumors attained a volume of 100 mm 3 and no animals survived beyond 50 days.
Acute dose regimen. No animal survived beyond 67 days. WA, RT, and HT, individually or in bimodality combinations, were not effective in significantly increasing the MST, but all these treatments produced some increase in overall survival; 50% of the treated animals survived for 44 to 48 days as against 38 days in the sham-treated group. However, the acute trimodality treatment significantly enhanced the MST. The first mortality in this group was recorded 48 days after treatment, that is, 16 days more than in sham-treated group, and 50% animals survived at 54 days. However, the overall survival was not much higher than after the other acute treatment groups (Figure 4) .
Fractionated dose regimen. WA, RT, and HT given individually produced a small increase in MST over the respective fractionated dose groups, but the overall survival remained almost similar to the latter. The combination of RT with HT resulted in significantly higher MST than after similar combinations in acute regimens, but the effect was not significant compared with the individual modalities in fractionated regimen. However, daily administration of WA before RT for 3 weeks significantly enhanced the MST (Table 1) compared with the RT fractionation alone as well as the single dose WA + RT treatment; 50% of the treated animals survived up to 70 days and the maximum survival time was 90 days, which was 38 days more than that after fractionated RT alone for 4 weeks. WA + HT did not show any advantage over the individual modalities in fractionated regimen, but gave a higher survival than their combination in acute dose regimen.
The combination of WA daily before RT and once a week HT significantly increased the MST to 105 days, a 2-fold increase from that obtained after acute trimodality treatment, and 20% survived for more than 120 days. The first mortality occurred at 89 days after treatment and 50% of the animals survived up to 100 days, compared to 48 days in the acute dose regimen. None of the other treatments could prolong the animal survival beyond 90 days ( Figure 5 ).
Discussion
The results of the present study suggest that B16F1 melanoma, which has a large hypoxic fraction, 9 responds better to gamma radiation when conventional dose fractions are used. Even though neither the single large dose treatment nor the fractionated irradiation could produce any complete or partial regression, the fractionated RT significantly increased the growth delay (by almost 12 days) from the single dose treatment. The higher tumor response observed in tumors exposed to fractionated RT could be attributed to reoxygenation of hypoxic cells in between the fractions, 10 making them more radiosensitive. 11 In the present study, fractionated RT resulted in an initial increase in tumor volume, followed by a gradual decrease. The initial increase in the tumor volume during fractionated radiotherapy has been reported by earlier studies. Progressive damage of the tumor vasculature results in increased vascular permeability and edema of the tumor. 12, 13 With further increase in radiation dose the clonogenic tumor cells decrease owing to reoxygenation of hypoxic cells, decreased ability of the cells to recover from potentially lethal damage and an increase in the sensitivity of cells to mitotic death, 14 collectively resulting in decrease in tumor volume. Fractionated radiotherapy induces a higher percentage of apoptosis in solid tumors compared with a single dose. 15 The increased growth delay after fractionated RT observed in the present study could be explained on the basis of a decrement in the clonogenic cells because of apoptosis and mitotic cell death of the reoxygenated cells attempting division.
Even though fractionated RT brought about a higher cell death and tumor growth delay, it was not sufficient to significantly increase the MST. After the initial regression the tumor grew at the same rate as in the animals receiving the acute RT, and all animals died of tumor burden. This indicates that RT alone is not able to completely eliminate the tumors with a size of 100 mm 3 or more. This was also true of the other single modalities, HT and WA, used in this study.
HT as a single modality treatment, either as an acute treatment or in fractionated regimen was less effective on tumor response and animal survival compared with RT. A single heat treatment may kill only the cells in the hypoxic region, which are highly sensitive to hyperthermia. 6 The remaining clonogenic cells may still be able to divide and cause increase in tumor volume. Even once a week heat treatment for 3 weeks had only a small advantage over the single dose. Our earlier study has demonstrated that thermotolerance develops in B16F1 melanoma during repeated HT, 7 which could explain the moderate effect of repeated HT on tumor growth kinetics compared with single heat treatment. Overall, HT did not show any beneficial effect over RT in reducing tumor growth and prolonging survival.
Daily WA treatment for 3 weeks did not have any pronounced effect on tumor regression. However, it produced a nonsignificant increase in growth delay and MST over that produced by single dose WA, as well as a small increase in MST over that produced by fractionated RT/HT treatment. Uma Devi et al 5 have reported that WA, by itself, has a weak tumor inhibitory effect, which is supported by the present study. Inhibition of mitosis, 16 generation of oxidative stress due to interaction of WA with sulfhydryl groups of proteins and GSH, 17 spindle poisoning property, 18 and inhibitory effect on protein, DNA and RNA synthesis can contribute to the cytotoxic activity of WA in tumors. In addition, recent studies have shown that it has an antiangiogenic property 19 and induces apoptosis in tumors. [20] [21] [22] Increase in MST of tumor bearing mice observed in the present study at a nontoxic dose (15 mg/kg) seems to indicate safety for prolonged treatment. Earlier study has shown that daily i.p. administration of 16 mg/kg (one fifth of LD 50 ) of WA for 1 month did not produce any normal tissue toxicity (unpublished findings). The increase in MST observed in WA treated group could be because of its modulatory action on the immune system. 23, 24 Several studies have demonstrated the improved efficacy and reduced normal tissue toxicity of bimodality treatments over RT alone. In the present investigation, the synergistic effect of RT + HT treatment (50% PR) in acute dose regimen could be because of the fact that HT kills radioresistant hypoxic cells and cells in the S-phase, which are radioresistant, 25 whereas radiation kills the well oxygenated cells. The decrease in PR observed in fractionated RT with weekly HT compared with acute RT + HT treatment could be because of the reoxygenation of hypoxic cells during fractionated radiation, which are resistant to HT. In addition, repeated HT can induce thermotolerance in the tumor tissue, which may reduce the therapeutic efficiency of HT given subsequently. We have demonstrated in our earlier study that thermotolerance developed in B16F1 melanoma decays gradually and a gap of 1 week between 2 HT treatments does not have any significant effect on GD. 7 The radiosensitizing effect of WA has been demonstrated by several in vivo 4, 5, 26 and in vitro studies. 27, 28 The present study has shown that administration of WA daily with conventional fractionated RT resulted in a significant increase in tumor growth delay, without producing any drug-related toxicity. Treatment for 3 weeks with WA + RT in fractionated regimen gave the maximum GD and MST among all the bimodality treatments. A daily dose of 15 mg/ kg for 3 weeks with 2 Gy RT, used in the present study, was well tolerated and no untoward effect due to the drug was noticed during the 120 days of observation, suggesting that this dose is safe and can be used for radiosensitization during conventional RT. In addition, by combining this dose it is possible to get a higher tumor response than that obtained by a higher dose of RT alone (40 Gy in 4 weeks, as against WA + 30 Gy for 3 weeks). The most significant observation of this study is that it is possible to reduce the total radiation dose and duration of treatment with this combination schedule.
WA in combination with HT, either in acute or fractionated regimen, did not produce any significant effect on tumor growth compared with the respective single modality treatments. It has been demonstrated by an earlier study that WA acts as a weak hyperthermic sensitizer. 5 The marginal increase in GD observed in WA + HT treatment in fractionated regimen could be a result of the accelerated decay in thermotolerance induced by WA. 7 However, compared with RT + HT and WA + RT treatment, WA + HT had inferior effect on tumor response. Thus it is evident that WA is a superior radiosensitizer than HT in treating a radioresistant tumor like B16F1 melanoma.
The results of the present investigation suggest that combination of all 3 modalities involving 15 mg/kg WA before every RT fraction and 1 HT every week immediately after RT for 3 weeks had a remarkable effect on tumor regression and regrowth and markedly enhanced the therapeutic outcome. The trimodality treatment produced 100% PR and also produced a highly significant increase in growth delay as well as MST compared with bimodality treatments. The effect of the fractionated dose regimen was significantly higher than the corresponding single modality regimen. Moreover, the trimodality combination for 3 weeks had a significantly higher tumor inhibitory effect as well as survival benefit compared with fractionated RT for 4 weeks. The MST was not significantly increased above that of RT alone when the treatment was given in acute doses, whereas it was increased to almost double that of the RT alone fractionated treatment as well as the acute trimodality treatment.
Thus, the present study has demonstrated that trimodality treatment using a nontoxic dose of WA daily before fractionated RT for 5 days a week for 3 weeks combined with 1 HT per week immediately after the RT fraction could give a higher therapeutic outcome than fractionated RT for 4 weeks. This trimodality combination with fractionated RT would have the additional advantages in (a) reducing the total radiation dose will reduce the normal tissue reactions, resulting in minimum side effects; (b) reducing the number of fractions will reduce the duration of treatment, thereby bringing down the cost of treatment; and (c) accelerating the decay of thermotolerance would increase the effect of weekly HT.
